{"entity":{"id":"sys6023","kind":"drug","name":"SYS6023","aka":[],"tldr":"SYS6023 is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER3.","summary":"SYS6023 is an antibody-drug conjugate developed by CSPC Megalith Biopharmaceutical. Its target is HER3 (the sponsor names HER3). The sponsor states: Antibody-drug conjugate targeting HER3, administered by intravenous infusion. ClinicalTrials.gov describes the intervention as: SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in HR-positive / HER2-negative breast cancer. The largest, NCT07597629, plans to enrol 36 participants with primary completion expected 2027-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of SYS6023","url":"https://clinicaltrials.gov/search?intr=SYS6023"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":["her3"],"drugs":[],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07597629"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"Antibody-drug conjugate targeting HER3, administered by intravenous infusion.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sys6023/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"target":[{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}],"trial":[{"id":"nct07597629","kind":"trial","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","route":"/trials/nct07597629/"}]}}